PL2614838T3 - Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka - Google Patents

Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka

Info

Publication number
PL2614838T3
PL2614838T3 PL11823663.7T PL11823663T PL2614838T3 PL 2614838 T3 PL2614838 T3 PL 2614838T3 PL 11823663 T PL11823663 T PL 11823663T PL 2614838 T3 PL2614838 T3 PL 2614838T3
Authority
PL
Poland
Prior art keywords
diquafosol
salts
treatment
hyaluronic acid
dry eye
Prior art date
Application number
PL11823663.7T
Other languages
English (en)
Inventor
Yuko Shichijo
Atsuyoshi Dota
Takashi Nagano
Masatsugu Nakamura
Asuka Sakamoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2614838T3 publication Critical patent/PL2614838T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Non-Alcoholic Beverages (AREA)
PL11823663.7T 2010-09-10 2011-09-09 Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka PL2614838T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010203198 2010-09-10

Publications (1)

Publication Number Publication Date
PL2614838T3 true PL2614838T3 (pl) 2016-10-31

Family

ID=45810785

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11823663.7T PL2614838T3 (pl) 2010-09-10 2011-09-09 Dikwafozol i kwas hialuronowy lub ich sole do zastosowania w leczeniu zespołu suchego oka

Country Status (19)

Country Link
US (1) US9006208B2 (pl)
EP (1) EP2614838B1 (pl)
JP (1) JP5956735B2 (pl)
KR (2) KR101707269B1 (pl)
CN (2) CN106729718A (pl)
AU (2) AU2011299851A1 (pl)
BR (1) BR112013005438B1 (pl)
CA (1) CA2810481C (pl)
DK (1) DK2614838T3 (pl)
EA (1) EA026680B1 (pl)
ES (1) ES2569246T3 (pl)
HK (1) HK1184686A1 (pl)
MX (1) MX336944B (pl)
MY (1) MY170198A (pl)
NZ (1) NZ608202A (pl)
PL (1) PL2614838T3 (pl)
SG (1) SG188482A1 (pl)
TW (1) TWI519301B (pl)
WO (1) WO2012033189A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201508591UA (en) * 2010-12-28 2015-11-27 Santen Pharmaceutical Co Ltd Ophthalmic solution comprising diquafosol, method for producing the same, and method for inhibiting formation of insoluble precipitate
MX353874B (es) 2012-03-26 2018-02-01 Santen Pharmaceutical Co Ltd Gotas para los ojos que contienen diquafosol.
JP6357228B2 (ja) 2013-07-10 2018-07-11 マトリックス バイオロジー インスティテュート 高い弾性を有するヒアルロナンの組成物およびその使用
US9289494B2 (en) 2013-11-20 2016-03-22 RestorTears, LLC Method of treating ocular disorders with compounds found in Harderian gland secretions
JP6267003B2 (ja) * 2014-02-27 2018-01-24 参天製薬株式会社 ジクアホソルまたはその塩およびレバミピドまたはその塩を組み合わせたことを特徴とする涙液分泌促進剤
RU2742032C2 (ru) * 2015-06-05 2021-02-01 Сантен Фармасьютикал Ко., Лтд. Терапевтическое средство против сухости глаз, характеризуемое нанесением на глаза пациентов с сухостью глаз, носящих гибкие контактные линзы
JP2017052723A (ja) * 2015-09-10 2017-03-16 株式会社Ｌｔｔバイオファーマ ドライアイ改善剤
WO2017053339A1 (en) 2015-09-24 2017-03-30 Matrix Biology Institute High elasticity hyaluronan compositions and methods of use thereof
KR20190068575A (ko) * 2016-10-14 2019-06-18 이콤 메디칼 게엠베하 안구 표면 항상성의 확립, 회복 및 보존 방법
JPWO2018074421A1 (ja) 2016-10-21 2019-08-29 ライオン株式会社 眼科用剤及び眼科用薬
CN107096016B (zh) * 2017-06-26 2021-04-06 蒋广伟 一种缓解视力疲劳的滴液
RU2652581C1 (ru) * 2017-07-03 2018-04-26 федеральное государственное бюджетное образовательное учреждение высшего образования "Приволжский исследовательский медицинский университет" Министерства здравоохранения Российской Федерации Способ лечения роговично-конъюнктивального ксероза
KR102108552B1 (ko) * 2018-05-15 2020-05-08 한국세라믹기술원 히알루론산 마이크로비드의 제조 방법 및 상기 히알루론산 마이크로비드의 용도
CN109260146A (zh) * 2018-10-12 2019-01-25 广州大光制药有限公司 地夸磷索钠眼用即用型凝胶滴眼液及制备方法
WO2020175525A1 (ja) 2019-02-27 2020-09-03 参天製薬株式会社 ジクアホソルまたはその塩、ビニル系高分子およびセルロース系高分子を含有する眼科用組成物
KR20240049646A (ko) * 2019-08-27 2024-04-16 산텐 세이야꾸 가부시키가이샤 디쿠아포솔 또는 그 염 및 폴리비닐피롤리돈을 함유하는 수성 안과용 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01115902A (ja) 1987-10-30 1989-05-09 Showa Sangyo Co Ltd ヒアルロン酸の製造法
US5900407A (en) 1997-02-06 1999-05-04 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with uridine triphosphates and related compounds
AU738907C (en) * 1997-02-06 2002-05-16 Merck Sharp & Dohme Corp. Dinucleotides and their use
US7223744B2 (en) * 1997-02-10 2007-05-29 Inspire Pharmaceuticals, Inc. Pharmaceutical formulation comprising dinucleoside polyphosphates and salts thereof
PT1012154E (pt) 1997-07-25 2004-08-31 Inspire Pharmaceuticals Inc Sais de di(5'-tetrafosfato de uridina), metodo para a sua preparacao, e suas utilizacoes
JP2003160491A (ja) 2001-09-11 2003-06-03 Santen Pharmaceut Co Ltd ジウリジンリン酸含有点眼液

Also Published As

Publication number Publication date
ES2569246T3 (es) 2016-05-09
AU2017200821A1 (en) 2017-03-02
HK1184686A1 (zh) 2014-01-30
US9006208B2 (en) 2015-04-14
BR112013005438A2 (pt) 2016-05-17
US20130172287A1 (en) 2013-07-04
TW201216971A (en) 2012-05-01
MX2013002677A (es) 2013-06-13
AU2011299851A1 (en) 2013-04-04
KR20130109130A (ko) 2013-10-07
JP2012077080A (ja) 2012-04-19
EP2614838B1 (en) 2016-04-20
BR112013005438B1 (pt) 2021-09-21
CN106729718A (zh) 2017-05-31
CA2810481C (en) 2018-06-19
WO2012033189A1 (ja) 2012-03-15
DK2614838T3 (en) 2016-05-02
AU2017200821B2 (en) 2018-08-30
EA026680B1 (ru) 2017-05-31
SG188482A1 (en) 2013-04-30
TWI519301B (zh) 2016-02-01
CN103096929A (zh) 2013-05-08
CA2810481A1 (en) 2012-03-15
MX336944B (es) 2016-02-03
JP5956735B2 (ja) 2016-07-27
KR20170018462A (ko) 2017-02-17
MY170198A (en) 2019-07-09
KR101707269B1 (ko) 2017-02-15
EP2614838A1 (en) 2013-07-17
EA201390364A1 (ru) 2013-08-30
NZ608202A (en) 2014-08-29
EP2614838A4 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
HK1184686A1 (zh) 用於治療乾眼症的地誇磷索和透明質酸或其鹽
IL261768B (en) Devices and methods for tissue treatment
EP2640461A4 (en) SYSTEMS AND METHOD FOR TREATING THE DRY EYE
HK1209788A1 (en) Methods and compositions for the treatment of lysosomal storage diseases
AP3482A (en) Branched 3-phenylpropionic acid derivatives and the use thereof
HK1201042A1 (en) Compositions for the treatment of dry eye
EP2800543A4 (en) DRY EYE TREATMENT SYSTEMS
EP2629736A4 (en) FABRIC TREATMENT
PL2521562T3 (pl) Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych
IL225793A0 (en) Methods and preparations for curing insulin-related medical conditions
PT2810599T (pt) Sistema de estimulação elétrica para o tratamento da apneia do sono
EP2763667A4 (en) ORGANONITRO THIOETHERIC COMPOUNDS AND MEDICAL USES THEREOF
HK1210941A1 (en) Modified hyaluronic acid derivatives and use thereof
PL2576782T3 (pl) SiRNA i ich zastosowanie w sposobach i kompozycjach do leczenia i/lub zapobiegania schorzeniom oczu
GB201001412D0 (en) Propolis and process for the treatment thereof
HK1196535A1 (zh) 鹽及醫藥用途
ZA201307058B (en) Use of polyaminoisoprenyl derrivatives in antobiotic or antisertic treatment
HK1216721A1 (zh) 治療肝臟疾病或病狀的用途和方法
HK1214771A1 (zh) 用於治療皮膚病的製劑
HK1185924A1 (zh) 用於醫療器械和裝置的功能納米結構殼聚糖塗層
PL2456445T3 (pl) Środek do leczenia chorób skóry
ZA201005770B (en) The treatment of damaged skin
ZA201505093B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the treatment of atherosclerosis
AU2012900286A0 (en) "Methods of treatment or prophylaxis"
GB0911581D0 (en) Compositions for use in the treatment of dry eye